Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Analysts' Corner
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, December 25, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), Gentium S.p.A. (ADR) (NASDAQ: GENT), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and MEDNAX Inc. (NYSE: MD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ARIAD Pharmaceuticals, Inc. Research Report
On December 20, 2013, ARIAD Pharmaceuticals, Inc. (ARIAD) announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for revised U.S. Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig® (ponatinib) that allows the immediate resumption of its marketing and commercial distribution. According to the Company, the USPI constitutes a revised indication statement and boxed warning, updated safety information, and recommendations about dosing considerations for prescribers. ARIAD added that Iclusig is now indicated for the treatment of adult patients with T315I-positive chronic myeloid leukemia or T315I-positive Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, and Chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia. Harvey J. Berger, M.D., Chairman and CEO of ARIAD, said, "In less than two months of suspending marketing and commercial distribution of Iclusig in the U.S., we addressed the issues raised by the FDA and now are able to market and distribute Iclusig again in the U.S. As we look ahead to re-launching Iclusig in the U.S. and fulfilling our post-marketing requirements, we will continue to focus on understanding the benefits and risks of Iclusig treatment in patients with resistant or intolerant Philadelphia-positive leukemias." The Full Research Report on ARIAD Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Gentium S.p.A. (ADR) Research Report
On December 20, 2013, Gentium S.p.A.'s (ADR) (Gentium) stock rose 2.82%, ending the day at $57.22. Over the previous three trading sessions, shares of Gentium gained 4.06%, compared to the Nasdaq Composite, which gained 2.01% during the same period. The Full Research Report on Gentium S.p.A. (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Salix Pharmaceuticals Ltd. Research Report
On December 20, 2013, Salix Pharmaceuticals Ltd.'s (Salix Pharmaceuticals) stock rose 2.38%, ending the day at $87.61. Over the previous three trading sessions, shares of Salix Pharmaceuticals gained 3.40%, compared to the Nasdaq Composite, which moved up 2.01% during the same period. The Full Research Report on Salix Pharmaceuticals Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
NPS Pharmaceuticals, Inc. Research Report
On December 20, 2013, NPS Pharmaceuticals, Inc.'s (NPS Pharmaceuticals) stock rose 5.65%, ending the day at $28.42. Over the previous three trading sessions, shares of NPS Pharmaceuticals gained 14.37%, compared to the Nasdaq Composite, which gained 2.01% during the same period. The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
MEDNAX Inc. Research Report
On December 19, 2013, MEDNAX Inc. (MEDNAX) announced that it has acquired Neonatology Center of Winchester, P.C., a neonatal physician group practice based in Winchester, Virginia. The Company said that this practice will become part of MEDNAX's Pediatrix Medical Group division, a national group practice that includes neonatal, maternal-fetal medicine, pediatric cardiology, and other pediatric specialty physicians. MEDNAX stated that it acquired Neonatology Center of Winchester P.C. for cash and expects the transaction to be immediately accretive to earnings. Commenting on the acquisition, Teresa Clawson, M.D., Medical Director of Neonatology Services at Winchester Medical Center, said, "Joining Pediatrix will afford us the opportunity to continue to develop quality improvement efforts in the care of babies while they are hospitalized, enhance research and education initiatives, as well as place energy into community and legislative efforts that affect change for their futures." The Full Research Report on MEDNAX Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.